EDP173

EDP173 is an investigational dual-targeting small interfering RNA (siRNA) therapeutic developed by Genor Biopharma for the treatment of hyperlipidemia and atherosclerotic cardiovascular disease (ASCVD). As part of Genor's oligonucleotide platform, EDP173 is designed to simultaneously silence two distinct mRNA targets involved in lipid metabolism. By inhibiting the expression of these targets, the drug aims to lower plasma lipid levels and reduce the risk of cardiovascular events associated with ASCVD. The specific biological targets of EDP173 have not been publicly disclosed, but the candidate is part of a broader cardiometabolic pipeline that includes other dual-targeting siRNAs and antisense oligonucleotides.